Financial giants have made a conspicuous bearish move on CRISPR Therapeutics. Our analysis of options history for CRISPR Therapeutics CRSP revealed 11 unusual trades.
Delving into the details, we found 9% of traders were bullish, while 90% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $203,500, and 5 were calls, valued at $185,621.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $85.0 for CRISPR Therapeutics over the recent three months.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CRISPR Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CRISPR Therapeutics's significant trades, within a strike price range of $40.0 to $85.0, over the past month.
CRISPR Therapeutics 30-Day Option Volume & Interest Snapshot
Noteworthy Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | SWEEP | BEARISH | 01/17/25 | $40.00 | $47.3K | 253 | 10 |
| CRSP | CALL | TRADE | NEUTRAL | 04/19/24 | $85.00 | $42.9K | 2.3K | 90 |
| CRSP | PUT | TRADE | NEUTRAL | 01/16/26 | $70.00 | $42.5K | 37 | 25 |
| CRSP | PUT | TRADE | BEARISH | 03/22/24 | $74.00 | $40.0K | 1.2K | 810 |
| CRSP | PUT | TRADE | BEARISH | 03/28/24 | $75.00 | $34.0K | 504 | 301 |
About CRISPR Therapeutics
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
After a thorough review of the options trading surrounding CRISPR Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of CRISPR Therapeutics
- With a volume of 866,092, the price of CRSP is up 0.78% at $84.4.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 63 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CRISPR Therapeutics with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
